Buyouts
Investing in business transformation
200+ direct/co-investments
Our team focuses on small and mid-market companies, investing both directly and in partnership with specialised private equity managers
Investments spanning a range of industries
Portfolios are diversified across five key sectors: healthcare, technology, consumer, business services and industrials
A track record that demonstrates consistent value creation
A strong track record of performance and value-add capabilities, proven across multiple economic cycles
Seizing the opportunity for change
Investors come to us for our experience and focus on small and mid-market buyout investments, sourced primarily from family and founder-owners. We seek to drive growth and transformation in the businesses we own. We leverage our global platform, and a network of specialised managers, to access high-potential investments.
Why it makes sense to tap into lower mid-market buyouts
Schroders Capital is a seasoned buyout investor. We focus on specialised market segments, with a global perspective. Our investors benefit from a network that we’ve developed since 1997. We believe the small and mid-market is where the best opportunities to maximise return can be found. Companies in this segment are less reliant on financial engineering, instead generating upside through operational improvements and transformed growth.
Global reach. Local networks.
Our global, institutional platform supports strong local teams working alongside specialist GPs. Through these partnerships we are a respected investor and valued for the experience and networks we can bring to those companies.
Private equity
Construction products distributor focused on high growth markets
A value-added distributor of construction products and materials. With a focus on construction waterproofing, they develop deep customer relationships through specific expertise, product selection guidance, design support and local availability.
Year of investment
2018
Geography
North America
Sector
Industrial
Type
Buyout
Private equity
Specialty pharmaceutical company focused on innovative dosage forms
Azurity is a leading specialist pharmaceutical company. Azurity offers dosage innovation and patient centric manufacturing and has substantial scale and synergies from complementary products, pipelines and capabilities.
Year of investment
2021
Geography
North America
Sector
Healthcare
Type
Buyout
Meet our buyouts team
A long-serving, stable team of respected private equity professionals, with diverse backgrounds and highly relevant experience in sourcing, evaluating and executing buyout investments.
Our other areas of expertise in private equity
BlueOrchard
We are impact investment pioneers with a 20+ year track record and a global reach of over 280 million people. Our goal? Combining social and environmental impact with a positive financial return. We have invested long-term in more than 100 emerging and frontier markets through a network of over 750 financial institutions. Learn about the opportunity for impact and return